Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Denali Therapeutics (NASDAQ:DNLI – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Profitability
This table compares Creative Medical Technology and Denali Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -100.39% | -94.90% |
| Denali Therapeutics | N/A | -54.94% | -42.15% |
Institutional and Insider Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Creative Medical Technology and Denali Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $3,000.00 | 1,351.57 | -$5.99 million | ($1.99) | -0.31 |
| Denali Therapeutics | $21.38 million | 149.14 | -$512.54 million | ($1.73) | -11.50 |
Creative Medical Technology has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Creative Medical Technology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for Creative Medical Technology and Denali Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| Denali Therapeutics | 1 | 2 | 12 | 1 | 2.81 |
Denali Therapeutics has a consensus price target of $36.15, indicating a potential upside of 81.72%. Given Denali Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Creative Medical Technology.
Summary
Denali Therapeutics beats Creative Medical Technology on 10 of the 14 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc. is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited. The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.
About Denali Therapeutics
Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California. Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
